Learn how Biointron's AbDrop™ speeds can revolutionize antibody discovery using Single B technology in our upcoming webinar!
Biointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for June 26th, 2025. This webinar will feature our speaker, Dr. Gang Liu, Associate Director of Biointron. Dr. Liu will delve into the captivating topic of "AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution," providing attendees with a rich and informative exploration of the latest trends and advancements in antibody discovery technologies. This webinar presents a not-to-be-missed opportunity for professionals, scholars, and all those passionate about the evolving landscape of antibody development, offering a chance to deepen their knowledge and engage with groundbreaking concepts in this vital field.
The seemingly agreeable path of antibody drug development from discovery to market in the modern world is actually filled with what-ifs, in many cases due to inadequate antibody molecules that are robust and “smart” enough to meet the ever-increasing research and clinical requirements. Single B cell screening is an up-to-date antibody discovery strategy that, unlike hybridoma technology, screens primary B cells to obtain diverse antibody candidates. As introduced in the presentation, Biointron’s single B cell screening platform (AbDrop™) is a microfluidic technology-driven, droplet-based, high throughput single B platform for antibody discovery. Integrated with high throughput NGS sequencing and antibody production capacity, AbDrop™ solution achieves antibody discovery goals in a timeline-expediting and diversity-protecting manner. As case studies presented demonstrate, this solution is especially effective for discovery campaigns like challenging targets, rare antibodies, and unique research requirements.

Dr. Gang Liu is Associate Director of Biointron. He has devoted himself to biological sciences and antibody therapeutics research for more than 20 years. Before joining Biointron, Dr. Liu worked in renowned biotech such as Genscript, and prestigious academia institutions, including Childrens Hospital LA, UC Irvine, and City of Hope Medical Center. Dr. Liu earned his Ph.D. degree from Academy of Military Medical Sciences in China, 2007.
AI is transforming antibody discovery, but better models only come from better d……
The antibody therapeutics sector is rapidly evolving, transitioning from traditi……
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured e……
当サイトでは、お客様の利便性向上のためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。
Biointronは、ウェブサイトの正常な動作を確保し、訪問者の利用状況を理解し、コンテンツとサービスを改善するために、クッキーおよび同様の技術を使用しています。必須クッキーはデフォルトで有効になっています。
「すべて許可」をクリックすると、分析クッキーやオプションクッキーを含むすべてのクッキーの使用に同意したことになります。「必須以外を拒否」をクリックすると、必須クッキーのみが使用されます。
クッキーの設定は、ウェブサイトの下部にある「クッキー設定」をクリックすることで、いつでも管理・変更することができます。
クッキーの使用方法および個人データの取り扱いについては、プライバシーポリシーをご確認ください。




